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Editorial challenges

The increase in human subject papers
has placed new demands on our peer
review process, especially as the increase was superimposed on a high
submission rate in other areas. We are
still in the process of adjusting to these
new needs. Glenn Heller (Memorial
Sloan-Kettering Cancer Center, New
York, NY) and Madhu Mazumdar
(Weill Cornell Medical College, New
York, NY) have essential roles as Consulting Biostatistics Editors. We also are
benefiting from the expert advice of a
number of referees who are familiar
with human research, several of whom
have joined our Advisory Editorial
Board. Most recently, we welcomed
David Hafler (Harvard Medical School,
Boston, MA), Kevin Tracey (North
Shore University Hospital, Manhasset,
NY), and Jean-Laurent Casanova (Necker
Medical School, Paris, France), who
bring broad expertise in autoimmunity,
inflammation, and infectious disease biology, respectively.

in a way that is expected of research
with mice. Nonetheless, the Editors
and most referees appreciate the constraints imposed by protocols that must
protect human subjects and, in each
case, the potential impact of the study
was judged to be high, in spite of these
limitations.

Evaluating human research

What are the Editors looking for when
they screen papers involving human
subjects? Three of the criteria are the
same as for all other papers: conceptual
novelty, state of the art approaches, and
the highest biological or therapeutic
importance. But there is one difference
with human papers relative to papers
with simpler experimental systems. Although new mechanistic insight is essential, we do not necessarily expect the
depth of the mechanistic workup to be
comparable. Some of the human studies
we have published involve a detailed
analysis of a very small number of patients, whereas others involve a larger
number of subjects. Typically, the investigators were not able to pursue and
firmly establish mechanism in one paper
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Experimental medicine in patients

The human subject papers that we have
published reflect a diversity of topics
and approaches. All are careful, systematic studies that provide new biological
insight, but very few have involved actual
experiments in patients using experimental or approved interventions to
understand human physiology. This is
where our research enterprise needs to
grow and this will require much more
support than it is currently receiving.
As scientists, we are accustomed to dissecting and analyzing a system in a reductionist way, often in genetically altered
animals, to understand what is going on
and in many cases to inspire future
treatments. But in human subjects there
is often a need to take a more integra1349
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A little more than a year ago, we published an editorial calling for papers describing research on human subjects
(1). Research on human subjects is becoming more feasible because of advances in methodology, and investigations on human subjects are needed to
advance the areas of human physiology
and disease covered by the Journal.
Patient-oriented research in particular
is often perceived as being applied
rather than basic research, but we reasoned that these demanding investigations can provide essential new biological insights and have an important place
in our Journal, even though the depth
of mechanistic analysis is of necessity
more limited than in research on simpler systems. To encourage submissions
of papers that involved human studies,
we made a commitment to judge them
on their capacity to advance the field
within the context of human research.
During the ensuing year, there
has been a striking increase in the
number of submissions involving human subjects. In parallel, the number
of accepted papers that required human subjects increased more than
threefold in 2004 compared with 2003,
with 10% of papers published in
2004 involving human subjects. We
also are pleased to have witnessed an
increased number of papers in which
human pathogens were studied but
without a need for human subjects. In
2004 the number of accepted papers
in this sphere was 5%, a twofold increase over 2003. These changes bring
some balance to experimental medicine
in the Journal, which clearly retains its
focus on “basic” research and disease
models in which deeper mechanistic
studies are possible. We hope that future studies in these more tractable experimental systems will be inspired by
findings in patients.
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vention in patients is a powerful form
of research, but it is currently a small
and relatively neglected part of our
profession. For research on patients to
grow we need to overcome many of
the obstacles and omissions that are
currently apparent in terms of training,
funding, and access to clinical-grade reagents (4).
A barrier to publishing in basic scientific journals with broad readerships
is an additional obstacle to the development of careers in patient-based research.
Surely the increase in submitted and
accepted papers that we have seen reflects
that investigators who study human subjects want to see their work published
in these journals. The problem has
been that most basic science journals
simply are not prepared to get excited
about the best findings that can be
made in human subjects. We are excited by the new insights into human
disease and physiology that we have

published over the past 18 months.
Nevertheless, the JEM and other journals
may not get to publish more experimental medicine in patients unless the
research community more broadly overcomes the difficulties encountered by
investigators who study human subjects.
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tive and interventional approach and
try to direct physiology in order to understand disease processes and initiate
new therapies. In this issue, Pascual and
colleagues investigate the role of specific cytokines in the pathogenesis of a
form of childhood arthritis. They obtained clues that interleukin-1 may be
involved, and show that blockade of
interleukin-1 results in marked amelioration of this disease (2). Also in this issue,
Chang and colleagues, having found
earlier indications that NKT cells
might be providing protection against
cancer, assessed the capacity of mature
dendritic cells, charged with a synthetic
glycolipid, to expand NKT cells in patients with advanced cancer. They discovered that the levels of NKT cells in
blood undergo prolonged expansion
and that this can be associated with increased adaptive immunity to a third
party cytomegalovirus antigen (3). The
systematic study of a problem by inter-

